Back

Real world registry of use of SGLT2i in patients with HFrEF followed in a non-tertiary hospital.

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: ePosters in interventional cardiology and pharmacology 2 Antidiabetic Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Mr Virgilio Martinez Mateo

General Hospital La Mancha Centro, Alcazar de San Juan (Spain)

6 More presentations in this session

Presentation thumbnail
Challenging the norm: the use of sublingual nitroglycerin in patients with severe aortic stenosis undergoing cardiac CT
Doctor A. Silva (Coimbra, PT)
Abstract Slides Video
Presentation thumbnail
Age differences in prescribing guideline-directed medical treatment in heart failure with mildly reduced and reduced ejection fraction
Doctor V. Lopes (Coimbra, PT)
Abstract Slides Video
Presentation thumbnail
Adherence to the guideline-directed medical therapy in chronic heart failure: insight from a University Hospital
Doctor M. Assamti (Oujda, MA)
Abstract Slides Video
Presentation thumbnail
Prescribing SGLT2 inhibitors in acute heart failure: considerations for dysglycemia status, heart failure phenotype, and kidney function
Doctor A. Amanova (Aktobe, KZ)
Abstract Slides Video
Presentation thumbnail
Use of SGLT2 inhibitors in real life: predicting left ventricular reverse remodelling.
Doctor V. De Simone (Legnago, IT)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in interventional cardiology and pharmacology 2

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Differences in the optimization of pharmacological treatment in patients with heart failure and reduced ejection fraction and advanced chronic kidney disease.
thumbnail
Congress Presentation
The impact of early SGLT2i inclusion in quadruple therapy for de novo patients: enhancing medication management and clinical outcomes
thumbnail
Congress Presentation
Temporal trends in guideline-directed medical therapy prescription and 30-day readmission after heart failure hospitalization

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources